VolitionRx Reports Q3 2026 Revenue Growth and Significant Debt Reduction
VolitionRx (VNRX) reported third-quarter revenue of $1.6 million, a 157% increase compared to the prior year, driven by accelerated recognition of deferred revenue. The company successfully narrowed its operating loss by 35% year-over-year through aggressive cost-reduction measures, including a 28% reduction in headcount and a 14% decrease in operating expenses. On the balance sheet, VolitionRx significantly deleveraged by paying down $5.0 million in convertible note debt since June 30, 2026, leaving only $0.7 million in outstanding notes. Management is targeting an operating cash burn of under $1.0 million per month by 2027 and is focusing on non-dilutive revenue streams such as licensing for its Capture-Seq technology in the multi-cancer early detection and minimal residual disease markets.
Topics: cash flow cost-cutting debt reduction operating loss reduction revenue growth